PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

Abstract

Following years in development, poly-adenosyl-ribose polymerase (PARP) inhibitors continue to advance the treatment of ovarian and breast cancers, particularly in patients with pathogenic BRCA mutations. Differences in clinical trial design have contributed to distinct indications for each of the PARP inhibitors. Toxicity patterns are also emerging that suggest agents differ in their normal tissue tolerance - beyond what might be expected by dose variations and/or exposure to prior treatment. PARP inhibitor resistance is an increasingly relevant issue as the drugs move to the forefront of advanced ovarian/breast cancer treatment, and is an active area of ongoing research. This review examines the PARP inhibitor clinical trials that have led to approved indications in ovarian and breast cancers, PARP inhibitor targets and pharmacological differences between the PARP inhibitors, emerging mechanisms of resistance, and key clinical questions for future development.

Keywords

poly-adenosyl-ribose polymerase inhibitors / poly-adenosyl-ribose polymerase inhibition / breast cancer / ovarian cancer / BRCA / homologous recombination deficiency / poly-adenosyl-ribose polymerase inhibitor resistance

References

[1] Flohr C,Radicella JP.Poly (ADP-ribosyl) ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein..Nucleic Acids Res2003;31:5332-37 PMCID:PMC203308

[2] Patel AG,Kaufmann SH.Nonhomologous end joining drives poly (ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells..Proc Natl Acad Sci U S A2011;108:3406-11 PMCID:PMC3044391

[3] Couto CA,Green JC,Siddaway R.PARP regulates nonhomologous end joining through retention of Ku at double-strand breaks..J Cell Biol2011;194:367-75 PMCID:PMC3153639

[4] Konstantinopoulos PA,Shapiro GI.Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer..Cancer Discov2015;5:1137-54 PMCID:PMC4631624

[5] Sfeir A.Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway?.Trends Biochem Sci2015;40:701-14 PMCID:PMC4638128

[6] Bryant HE,Thomas HD,Flower D.Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase..Nature2005;434:913-7

[7] Farmer H,Lord CJ,Johnson DA.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy..Nature2005;434:917-21

[8] Durkacz BW,Gray DA.(ADP-ribose) n participates in DNA excision repair..Nature1980;283:593-6

[9] Purnell MR.Novel inhibitors of poly (ADP-ribose) synthetase..Biochem J1980;185:775-7 PMCID:PMC1161458

[10] Calvert H.The clinical development of inhibitors of poly (ADP-ribose) polymerase..Ann Oncol2011;22:suppl_1i53-9

[11] Calabrese CR,Thomas HD,Wang LZ.Identification of potent nontoxic poly (ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies..Clin Cancer Res2003;9:2711-8

[12] Plummer R1,Middleton M,Evans J.Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors..Clin Cancer Res2008;14:7917-7923 PMCID:PMC2652879

[13] Rottenberg S,Kersbergen A,Nygren AO.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs..Proc Natl Acad Sci U S A2008;105:17079-84 PMCID:PMC2579381

[14] Fong PC,Boss DS,Mergui-Roelvink M.Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval..J Clin Oncol2010;28:2512-9

[15] Kaye SB,Matulonis U.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer..J Clin Oncol2011;30:372-9

[16] Domchek SM,Shapira-Frommer R,Audeh MW.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy..Gynecol Oncol2016;140:199-203 PMCID:PMC4992984

[17] Audeh MW,Penson RT,Powell B.Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial..The Lancet2010;376:245-51

[18] Kaufman B,Schmutzler RK,Friedlander M.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation..J Clin Oncol2014;33:244-50 PMCID:PMC6057749

[19] Kristeleit RS,Oaknin A,Ray-Coquard IL.Clinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)..Ann Oncol2016;27:856O

[20] Kristeleit R,Burris HA,LoRusso P.A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors..Clin Cancer Res2017;23:4095-106

[21] Swisher EM,Oza AM,Giordano H.Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial..Lancet Oncol2017;18:75-87

[22] Ledermann J,Gourley C,Vergote I.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer..N Engl J Med2012;366:1382-92

[23] Mirza MR,Herrstedt J,Oza AM.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer..N Engl J Med2016;375:2154-64

[24] Coleman RL,Lorusso D,Oza AM.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial..The Lancet2017;390:1949-61 PMCID:PMC5901715

[25] Aghajanian C,Goff BA,Teneriello MG.OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer..J Clin Oncol2012;30:2039-45 PMCID:PMC3646321

[26] Coleman RL,JHerzog T,ArmstrongColeman DK.Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial..Lancet Oncol2017;18:779-791 PMCID:PMC5715461

[27] Moore K,Scambia G,Oaknin A.Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer..N Engl J Med2018;379:2495-505

[28] Spriggs DR.Progress in BRCA-Mutated Ovarian Cancer..N Engl J Med2018;379:2567-68

[29] Pujade-Lauraine E,Selle F,Penson RT.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial..Lancet Oncol2017;18:1274-84

[30] Liu JF,Birrer M,Buckanovich RJ.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study..Lancet Oncol2014;15:1207-14 PMCID:PMC4294183

[31] Oza AM,Benzaquen AO,Mathijssen RH.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial..Lancet Oncol2015;16:87-97

[32] Konstantinopoulos PA,Vidal GA,Fleming GF.TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib+ pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort..J Clin Oncol2018;36:106

[33] Robson M,Senkus E,Domchek SM.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation..N Engl J Med2017;377:523-33

[34] Litton JK,Ettl J,Gonçalves A.Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation..N Engl J Med2018;379:753-63

[35] Pahuja S,Appleman LJ,Stoller RG.A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC)..J Clin Oncol2015;33:1015

[36] Kummar S,Morgan R,Puhalla SL.A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas..Clin Cancer Res2012;18:1726-34 PMCID:PMC3306481

[37] Coleman RL,Bell-McGuinn K,Gray HJ.A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—an NRG oncology/gynecologic oncology group study..Gynecol Oncol2015;137:386-91 PMCID:PMC4447525

[38] Murai J,Renaud A,Ji J.Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib..Mol Cancer Ther2014;13:433-43 PMCID:PMC3946062

[39] Plummer ER,Cresti N,Drew Y.First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker..J Clin Oncol2018;36:2505

[40] Plummer R,Aissat-Daudigny L,Moachon G.Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors..Cancer Chemoth Pharm2014;74:257-65 PMCID:PMC4112042

[41] Awada A,Varga A,Frenel JS.An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors..Anti-cancer Drugs2016;27:342-8

[42] O’Shaughnessy J,Danso MA,Rugo HS.Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer..J Clin Oncol2014;32:3840-7

[43] Patel AG,Flatten KS,Kaufmann SH.Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro..Clin Cancer Res2012;18:1655-62 PMCID:PMC3306513

[44] Gagné JP,Lo KS,Hendzel MJ.Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes..Nucleic Acids Res2008;36:6959-76 PMCID:PMC2602769

[45] El-Khamisy SF,Suzuki H.A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage..Nucleic Acids Res2003;31:5526-33 PMCID:PMC206461

[46] Ceccaldi R,Amunugama R,Primack B.Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair..Nature2015;518:258-62 PMCID:PMC4415602

[47] Mateos-Gomez PA,Nair N,Lazzerini-Denchi E.Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination..Nature2015;518:254-7 PMCID:PMC4718306

[48] Murai J,Das BB,Zhang Y.Trapping of PARP1 and PARP2 by clinical PARP inhibitors..Cancer Res2012;72:5588-99 PMCID:PMC3528345

[49] Caldecott KW.Protein ADP-ribosylation and the cellular response to DNA strand breaks..DNA repair2014;19:108-113

[50] Hopkins TA,Rodriguez LE,Donawho CK.Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors..Mol Cancer Res2015;13:1465-77

[51] Hopkins TA,Ellis PA,DiGiammarino EL.PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow..Mol Cancer Res2019;17:409-419

[52] Grundy GJ,Zeng Z,Hoch NC.PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2)..Nat Commun2016;7:12404 PMCID:PMC4992063

[53] Knezevic CE,Rix LLR,Kuenzi BM.Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets..Cell Chem Biol2016;23:1490-1503 PMCID:PMC5182133

[54] Puhalla S,Pahuja S,Tawbi HAH.Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt)..J Clin Oncol2014;32:2570

[55] Li J,Sha X,Wu J.Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics..Clin Cancer Res2014;20:3931-44 PMCID:PMC4151156

[56] Norquist B,Pennil CC,Gross J.Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas..J Clin Oncol2011;29:3008-15 PMCID:PMC3157963

[57] Barber LJ,Chen L,Kozarewa I.Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor..J Pathol2013;229:422-9

[58] Kondrashova O,Shield-Artin K,Teng NNH.Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade ovarian carcinoma..Cancer Discov2017;7:984-998 PMCID:PMC5612362

[59] Goodall J,Yuan W,Porta N.Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition..Cancer Discov2017;7:1006-17 PMCID:PMC6143169

[60] Quigley D,Wyatt AW,Foye A.Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors..Cancer Discov2017;7:999-1005 PMCID:PMC5581695

[61] Isono M,Oike T,Sato H.BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation..Cell Rep2017;18:520-32

[62] Bunting SF,Wong N,Polato F.53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks..Cell2010;141:243-54 PMCID:PMC2857570

[63] Hurley RM,Visscher DW,Harrell MI.53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer..Gynecol Oncol2019;153:127-134 PMCID:PMC6430710

[64] Xu G,Brandsma I,Mistrik M.REV7 counteracts DNA double-strand break resection and affects PARP inhibition..Nature2015;521:541-4 PMCID:PMC4671316

[65] Chaudhuri AR,Ding X,Duarte AA.Replication fork stability confers chemoresistance in BRCA-deficient cells..Nature2016;535:382-7 PMCID:PMC4959813

[66] Hill SJ,Roberts EA,Muto MG.Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids..Cancer Discov2018;8:1404-21 PMCID:PMC6365285

[67] Gogola E,de Ruiter JR,Schmid JA.Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality..Cancer Cell2019;35:950-952 PMCID:PMC6561720

[68] Godoy H,Beck A,Lele S.Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome..Int J Gynecol Pathol2011;30:139-44 PMCID:PMC5049508

[69] Mazzotta A,De Summa S,Simone G.Nuclear PARP1 expression and its prognostic significance in breast cancer patients..Tumour Biol2016;37:6143-53

[70] Bitler BG,Wheeler LJ.PARP inhibitors: Clinical utility and possibilities of overcoming resistance..Gynecol Oncol2017;147:695-704 PMCID:PMC5698126

[71] Kondrashova O,Nesic K,Ho GY.Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma..Nat Commun2018;9:3970 PMCID:PMC6162272

[72] Neijenhuis S,Miller R,Ashworth A.Identification of miRNA modulators to PARP inhibitor response..DNA Repair2013;12:394-402

[73] Do K,Ji J,Freshwater T.Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors..J Clin Oncol2015;33:3409-15 PMCID:PMC4606059

[74] Moore KN,Geller MA,Cloven NG.QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received≥ 3 prior chemotherapy regimens..J Clin Oncol2018;36:5514

[75] Jiao S,Yamaguchi H,Chen MK.PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression..Clin Cancer Res2017;23:3711-20 PMCID:PMC5511572

[76] Vinayak S,Schwartzberg LS,McCann GAL.TOPACIO/Keynote-162: Niraparib+ pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial..J Clin Oncol2018;36:1011

[77] Teo MY,Ostrovnaya I,Kania BE.Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers..J Clin Oncol2018;36:1685-94 PMCID:PMC6366295

[78] Nolan E,Policheni AN,Vaillant F.Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer..Sci Transl Med2017;9:eaal4922 PMCID:PMC5822709

[79] Turner NC,Fasching PA,Telli ML.A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)..J Clin Oncol2015;33:TPS1108

[80] Somlo G,Arun BK,Garcia AA.Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic brea..Clin Cancer Res2017;23:4066-76 PMCID:PMC5540749